

## **Rescheduled Webcast: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIIRx**

April 23, 2012

CARLSBAD, Calif., April 23, 2012 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Clinical Development Plans for ISIS-APOCIIIIRx  
When: Friday, May 4, 2012 at 11:00 a.m. ET / 8:00 a.m. PT  
Where: [www.isispharm.com](http://www.isispharm.com)  
How: Live on the Internet. Simply log onto our Web site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [www.isispharm.com](http://www.isispharm.com).

### **ABOUT ISIS PHARMACEUTICALS, INC.**

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [www.isispharm.com](http://www.isispharm.com).

SOURCE Isis Pharmaceuticals, Inc.